The effects of neonatal passive immunization against GHRH on bone was examined in male and female rats. Pups were treated subcutaneously with GHRH-antiserum (GHRH-Ab) from day 1 to day 10 of age. Bone mineral content (BMC) and bone mineral density (BMD) were evaluated at monthly intervals until 7 months. Markers of bone resorption (urinary lysylpyridinoline, LP), bone formation (serum osteocalcin, OC) and serum IGF-I were measured at 2, 3 and 7 months. In male rats, GHRH-Ab did not modify BMC and BMD when compared with controls. In contrast, female rats demonstrated lower whole body and femoral BMC and BMD from 2 to 7 months of age. Reduced bone growth in the females was associated with lower IGF-I levels than controls at 2 and 3 months of age, whereas in males IGF-I titers did not change during the period of the study. LP excretion was higher in GHRH-Ab-treated rats at 2 and 3 months in both sexes. In females, no difference in OC values was recorded, whereas in GHRH-Ab-treated males, there was an increase in OC levels at 2 and 3 months. These data indicate that transient GHRH deprivation induces an osteopenic effect in female rats which is not evident in male rats.
Introduction
It is well known that growth hormone (GH) is an important regulator of bone remodeling and growth (Parfit 1991 , Ohlsson et al. 1998 . Children with GH deficiency have significantly reduced bone mass compared with control subjects (Saggese et al. 1993) . Reduced bone mass is also observed in adults with childhood-onset GH deficiency (De Boer et al. 1994) . Low bone mineral content (BMC) and bone mineral density (BMD) are observed in adult-onset GH deficiency (Holmes et al. 1994) , although more pronounced consequences of GH deficiency on bone mass is seen in adults with childhoodonset disease compared with adult-onset disease (Kaufman et al. 1992 , Rosen et al. 1993 . This evidence emphasizes the importance of GH in both the acquisition and the maintenance of bone mass (Johannsson & Bengtsson 1997) . Clinical correlation with these observations is difficult since GH-replacement trials in humans have great variability in the doses and duration of treatment. Hence, it is difficult to draw conclusions on the later development of bone mass due to GH deprivation during childhood. The effects of GH on bone may be direct or, more likely, mediated by GH-induced production of insulin-like growth factor (IGF)-I (Rosen & Donahue 1998) . GH stimulates the proliferation and function of osteoblasts by binding to specific binding sites present in these cells and by stimulating the production and the release of IGF-I and IGF-binding proteins via autocrine/paracrine and endocrine mechanisms. IGFs have also been implicated in stimulation of osteoclast formation and function, leading to the view that the GH/IGF system is involved in the coupling between bone resorption and bone formation (Eriksen et al. 1996) . In turn, the GH/IGF system has also been shown to mediate the effects of other anabolic factors such as thyroid hormones and steroids (Lackey et al. 1999 , Prakasam et al. 1999 .
The interaction of the GH/IGF system with sex steroids is complex. Some authors reported that GH deficiency in rats, as well as in humans, is accompanied by delayed pubertal development (Bartlett et al. 1990 , Holmes & Shalet 1996 whereas other authors reported no significant disturbance in sexual maturation in GH-deprived rats (Gruaz et al. 1994) . Sex steroids increase GH secretion and synthesis as well as the production of various components of the IGF system (Lackey et al. 1999) . Reciprocally, IGF-I has a role in the regulation of sex steroids synthesis and metabolism (Lackey et al. 1999) .
In addition to the effect on circulating GH, gonadal steroids act before puberty to exert permanent effects on the sexual dimorphic pattern of GH pulsatile secretion in later life (Gatford et al. 1998) . Numerous studies have demonstrated an interaction between sex steroids and GH on bone. In mice, intact ovaries are a prerequisite for the stimulatory effect of GH on BMC (Sandstedt et al. 1996) ; in ovariectomized rats, high doses of GH are needed to exert an anabolic effect on bone (Mosekilde et al. 1998) , suggesting that estrogen amplifies the GH effect on bone. In castrated rats, GH and testosterone act independently to produce their anabolic effects on bone mass and size (Prakasam et al. 1999) . From these data it appears that there are gender differences in the bone anabolic response to GH replacement therapy; however, whether or not bone changes due to impairment of GH/IGF axis differ in female and male rats has not yet been shown. In the rat, sexual differentiation of brain centers regulating the somatotrope axis occurs shortly after birth (Nurhidayat et al. 2001) .
In this study we investigated, in male and female rats, the effects of GH-releasing hormone (GHRH) deprivation in early postnatal life on subsequent acquisition and maintenance of bone mass. Long-term changes of somatotrope function were induced by neonatal passive immunization of rat GHRH (Wehrenberg et al. 1984 , Cella et al. 1990 ).
Materials and Methods

Animals
Pregnant Sprague-Dawley rats (Harlan, Italy) were purchased one week before the expected time of parturition and housed under controlled conditions (22 2 C, 65% humidity, 12 h light/12 h darkness cycle). The date of delivery was designated as 'postnatal day zero'. After birth, all pups were sexed by assessing the genito-anal distance and pups were culled to establish a standard litter size of 12 pups. Pups were weaned on postnatal day 20. After weaning all rats were housed individually to allow a controlled environment. Animals received a standard diet (Charles River, Calco, Italy) and water, both available ad libitum. Body weight was monitored once a month during the study. In all, about 50 rats were used. All experimental procedures were approved by the Ethics Committee of the Department of Pharmacology of the University of Milan.
Drugs
The antiserum against rat GHRH (GHRH-Ab) was prepared and validated by one investigator (W W). The GHRH-Ab has repeatedly been found to significantly inhibit GH secretion and growth in rats (Wehrenberg et al. 1984 , Wehrenberg 1986 , Cella et al. 1990 .
Characterization of the antiserum showed that it was directed towards the GHRH carboxy terminal. It cross-reacted with synthetic human, bovine and porcine GHRH by less than 4%. The antiserum did not cross-react with peptides that have considerable sequence homology with GHRH, including secretin, glucagon, vasoactive intestinal peptide, gastrin, motilin, bradykinin, and angiotensin.
Biochemical analysis
Total serum IGF-I concentrations were measured by RIA using a commercial kit (Diagnostic Systems Laboratories Inc., Webster, TX, USA). The detection limit of the assay was 21 ng/ml. The interassay variation was 3·2%, while the intra-assay variation was 3·8%.
Total urinary lysylpyridinoline (LP) levels were measured by reverse-phase high-performance liquid chromatography using a commercial kit (Immunodiagnostik AG, Bensheim, Germany). Briefly, urine samples were hydrolyzed followed by extraction on cellulose cartridges. LP was separated by reverse-phase high-performance liquid chromatography and measured fluorometrically (excitation 295 nm; emission 400 nm) utilizing the native fluorescence. The detection limit was 7·3 pmol/ml. The interassay variation was 8·4%. The total daily excretion of LP was corrected for creatinine excretion and expressed as nM/mM creatinine (LP/Cr). Urinary creatinine was measured colorimetrically using a commercial kit (Sigma Diagnostics Inc., Milano, Italy). Urinary LP samples from the same rat were measured in a single run.
Total serum osteocalcin (OC) was determinated using a commercial immunoenzymatic kit (Biomedical Technologies Inc., Stoughton, MA, USA). Intra-assay and interassay variations were 4% and 7% respectively.
Dual energy X-ray absorptiometry (DEXA)
All rats were anesthetized with ketamine hydrochloride (70 mg/kg, i.p.) plus xylazine (7 mg/kg, i.p.) and scanned with an Hologic QDR-1000 instrument (Hologic Inc., Waltham, MA, USA) using a small animal software package. The rat whole body scan protocol was used to scan and analyze the whole rat. The high resolution scan protocol was used to scan and analyze the left femur. Three regions of interest (ROI) were chosen: the entire femur, the femoral distal metaphysis and middle diaphysis. The software provided the total area (cm 2 ) of the planar image of selected segments, and the BMC (mg) and BMD (mg/cm 2 ) of the ROI. Coefficients of variation were 0·9% for whole body BMC, 1·2% for whole body BMD, 3% for femoral BMC and 1% for femoral BMD. The precision and accurancy of the DEXA method for determination of BMD in small laboratory animals have been widely validated (Paiagua et al. 1988 , Ammann et al. 1992 .
Experimental procedure
Starting on postnatal day 1 female and male pups were randomly divided into two groups: control and experimental animals. Female or male pups belonging to the experimental group were injected subcutaneously with 50 µl GHRH-Ab at six different times after birth (days 1, 2, 4, 6, 8 and 10 of age), and those belonging to the control group were injected with equal amounts of normal rabbit serum (NRS). After treatment pups were maintained with their mothers. The dose and timing of GHRH-Ab were chosen based on previous studies (Cella et al. 1990) .
In all rats BMC and BMD were evaluated at 2 and 3 months of age; thereafter, on the basis of the results obtained, bone parameters were evaluated monthly in females and every other month in males until month 7. We chose to record bone parameters beginning with the second month of age since, at this time, the rate of somatic growth starts to slow down. At 2, 3, and 7 months of age animals were placed in metabolic cages (Techniplast, Gazzada, Varese, Italy) for the collection of 24-h urine samples for measurement of LP, a marker of bone resorption. Urine samples were immediately frozen and stored at 20 C until assayed. Blood samples for measurement of OC, a marker of bone formation, and IGF-I were drawn, under light ether anesthesia, by retroorbital venous plexus puncture at the same time intervals. Serum was stored at 80 C until assayed.
Statistical analysis
Statistical analysis was performed by a statistical package (PRISM, GraphPad Software, San Diego, CA, USA). All data are shown as means S.E. Mean values for treated and control groups were compared at the same time by two-tailed unpaired t-test. Within each group, biochemical changes with time were tested by one-way repeated measures ANOVA, followed by Bonferroni multiple range test. A Fisher exact test was applied for statistical evaluation of the onset of puberty in female treated and control rats. A probability of P<0·05 was considered significant.
Results
Body weight measurements and sexual maturation
Impairment of the GHRH/GH system in female rats resulted in a significant and sustained reduction in body weight compared with control rats. In contrast, in GHRH-Ab-treated males, there was only a transient reduction in body weight recorded at 2 months of age (Table 1 ). In female rats evaluation of the onset of puberty by recording vaginal opening showed a significant (P<0·02) delay in the immunized rats as compared with controls. In fact, all GHRH-Ab-treated rats had a closed vagina until 38 days. Vaginal opening in control NRStreated female rats occurred between 33 and 38 days of age. Three of eight females fell on the former date and five of eight rats fell on the latter date. All animals had an opened vagina at 44 days.
Biochemical parameters
In control NRS-treated females, circulating IGF-I levels were significantly higher at 2 and 3 months of age as compared with values detected at 7 months. In GHRHAb-treated females, IGF-I values at 2 and 3 months were significantly lower than those of control animals whereas there were no differences in IGF-I levels at 7 months. In male rats IGF-I concentrations were not affected by either time or treatment so that this resulted at 7 months in serum IGF-I concentrations higher than those of females (Fig. 1A) . In control rats of either sex, the urinary excretion of LP significantly decreased with time. This may have reflected changes in bone turnover which is known to be higher in young rats as compared with adults. In female rats, GHRH-Ab caused a significant increase in LP excretion at 2 and 3, but not at 7 months of age (Fig. 2B) . This pattern was mimicked in GHRH-Abtreated male rats ( Fig. 2A) . Consistent with the coupling of bone resorption to bone formation the pattern of OC decreased with time similarly to that of LP in control rats of either sex. OC values in GHRH-Ab-treated female rats were not significantly different from those of NRS-treated animals. In male GHRH-Ab-treated rats there was a significant increase in serum OC levels at 2 and 3 months but not at 7 months of age (Fig. 1B) .
BMC and BMD of whole skeleton as measured by DEXA
In GHRH-Ab-treated females whole body bone areas were lower than those of NRS-treated rats at all times studied, although the decrease reached statistical significance only at 3 months of age. GHRH-Ab treatment caused a significant reduction in both whole skeleton BMC and BMD values in comparison with those measured in control-treated rats. Again, the peak decrement occurred at 3 months. In males there was no difference between GHRH-Ab-treated and control animals in all bone parameters irrespective of the time of observation (Table 2) .
BMC and BMD of femur as measured by DEXA
In females, GHRH-Ab treatment caused a significant reduction of femoral area and BMC at all times measured. The greater decrease in femoral BMC than in femoral area accounts for the significant reduction in BMD present.
This reduction finally subsided at 7 months of age. Again, male rats did not show any difference in femoral bone parameters (Table 3 ). In females, further analysis of bone parameters disclosed a higher sensitivity of cortical (femoral diaphysis) than cancellous (femoral metaphysis) bone to GHRH-Ab treatment. In fact, in GHRH-Abtreated rats only a transient decrease in both BMC and BMD was detected at femoral metaphysis at 2 months while, at femoral diaphysis the reduction in BMC and BMD was still statistically significant up to 5 months of age (Table 4) .
Discussion
One interesting finding that emerges from our study is that female rats, as far as bone metabolism is concerned, are more sensitive than male rats to transient deprivation of GHRH. In fact, passive immunization against GHRH during neonatal life induced in the former a reduction in BMC and BMD lasting to the end of the experiment. Data on circulating titers of IGF-I showed that there was a time-related decline in control females, but not in control males that maintained unaltered levels of IGF-I throughout the study. In GHRH-Ab-treated females, IGF-I levels lower than controls at 2 and 3 months would indicate an impaired function of the somatotrope axis, also implied by a sustained reduction in body growth. In GHRH-Ab-treated males, reduction in body growth was evident only at 2 months of age. Sexual dimorphism in hypothalamic-pituitary factors regulating GH synthesis and secretion may account for the more severe impairment of somatotrope function in female than male rats (Gatford et al. 1998) . Reportedly, hypothalamic GHRH mRNA and the number of GHRH neurons are higher in male than female rats (Nurhidayat et al. 1999) and the presence of the ovary during postnatal life inhibits the development of GHRH-containing neurons in the arcuate nucleus of the hypothalamus 
P<0·01 vs controls of the same age, t-test. (Nurhidayat et al. 2001) . Moreover, recent studies on the ontogenetic pattern of the receptor for the newly identified GH secretagogue (GHS-R), ghrelin, have revealed higher pituitary GHS-R mRNA concentrations in 30-day-old male rats than female rats (Kamegai et al. 1999) . Collectively, the different sensitivity of male and female rats to GHRH-Ab treatment would indicate that females, at least during the early postnatal period, are more dependent on GHRH function than males. Previous studies have shown that the different interaction between sex steroids and the GH/IGF-I axis is associated with the sexual dimorphic rate of body and skeletal growth (Wehrenberg & Giustina 1992) . Along this line, in our study increments in body weight and bone mass of control male rats were constantly higher than those of the female counterparts.
The growth effects of GH are either direct or mediated via IGF-I synthesis in various tissues. During puberty, somatic and skeletal growth in either sex are connoted by elevation in plasma IGF-I levels, whereas in adulthood the pattern of IGF-I secretion is differently influenced in the two sexes by gonadal steroids (Gabriel et al. 1992) . A change from a stimulatory to an inhibitory influence on IGF-I has been reported for estradiol at the transition to adulthood in both humans (Argente et al. 1993) and monkeys (Wilson 1998) .
In control male and female rats the maximal incremental change in bone mass occurred from 2 months to 5 months of age, whereas after 5 months changes in all bone parameters were minimal, thus indicating that at this age the animals were reaching peak bone mass. These data are in agreement with those of previous studies showing that growing rats (from 2 to 5 months old) increase bone mass by longitudinal bone growth and by periosteal expansion at either appendicular skeleton or vertebral bodies (Ortoft et al. 1999) .
It has also been reported that starting from 2 months onwards the cancellous bone mineralizing surface decreases, thereby denoting an age-related reduction in bone turnover (Ortoft et al. 1999) . In the present study, there was a significant decrease in markers of bone resorption (LP) and bone formation (OC), which indicates a decrease in bone turnover during growth in both sexes. In female rats, neonatal impairment of the GH/IGF axis by passive immunization against GHRH markedly delayed bone growth (as shown by bone areas) and mineral accrual (BMC). In fact, GHRH-Ab-treated females, at different time-intervals investigated, had a body weight and BMD comparable to those of 1-month younger controls. The reduction in mineral accrual was greater than that in bone area, therefore BMD was also reduced. In particular, femoral bone area was more severely impaired than whole body bone area, since in GHRH-Ab-treated rats, only femoral areas were significantly lower than those of the age-matched controls at almost all time intervals investigated. The more pronounced sensitivity of the femur to the impaired function of the somatotrope axis is in keeping with the promoting activity of GH on longitudinal bone growth and periosteal bone formation (Ohlsson et al. 1998) and, conversely, with the suppression of longitudinal growth-associated bone gain of GH deficiency (Yeh et al. 1995) . Consistent with this view, the impairment of GHRH function caused a significant BMC decrease at diaphyseal and metaphyseal sites. Considering that changes with age in diaphyseal BMC, expressed as a percentage, are superimposable on V SIBILIA and others · Neonatal GHRH immunization and bone massthose of the metaphysis, it cannot be ruled out that the relatively greater surface area of the diaphysis was responsible for the significant BMD decrease, evident only at this site. Reportedly, DEXA does not take into account bone volume (Nelson & Koo 1999) , therefore femoral area BMD in GHRH-Ab-treated females could have been reduced because the measurement was size adjusted in two dimensions, length and width, but not depth. Nevertheless, the decrease in femoral area and BMC in GHRH-Ab-treated female rats indicates that they have a smaller femur than controls. In this context, it is important to consider that the normal bone growth and development is determined by complex interactions between GH, sex steroids and mechanical forces which impinge upon the skeleton (Riggs et al. 2002) . The GHRH-Ab-treated females had a body weight always lower than controls, thus their femur was less exposed to weight-bearing stress. Thus it is likely that the decreased mechanical loading might have contributed to the delay in femoral bone growth.
A number of studies support the notion that the local production of IGF by GH (Turner 1992 ) and estrogens (Riggs et al. 2002) play an important role as mediators of the mechanical strain-related increase in bone mass. Thus the current finding that deficiency of GHRH function delayed vaginal opening would indicate the existence of an impaired estrogen milieu. Other authors (Gruaz et al. 1994) have not observed a delay in sexual maturation in female GHRH-Ab-treated rats, a difference likely due to immunization starting at a later postnatal date i.e. at 15 days.
It is worth noting that at the end of the experiment when peak bone mass was attained, reduction in BMD due to GHRH impairment was detectable for whole body bone density but not for total femoral density. It is recognized that whole body measurement by DEXA is a measure that includes changes in bone size and shape (Nelson & Koo 1999) ; thus whole body BMD decrease might reflect a net bone loss in skeletal areas other than the femur. In this context, it is feasible that the decrease in whole bone mass results from the lack of a positive interaction between GH/IGF and estrogens, since the latter not only modulate circulating GH/IGF levels but also increase GH receptor number and potentiate GH action on osteoblasts (Slootweg et al. 1997) . Furthermore, the protective effect of estrogens on cancellous bone is diminished in hypophysectomized rats (Yeh et al. 1997b) , and estrogens plus GH exert additive beneficial effects on cancellous bone in conditions of pituitary and ovary deficiency (Yeh et al. 1997a) . The whole body osteopenia of GHRH-Abtreated female rats would be the result of increased bone resorption not fully counterbalanced by a secondary increase in bone formation. In fact, the excretion of LP, the specific marker of bone collagen degradation, significantly increased in these rats, whereas no change occurred in serum OC, the marker of bone formation.
In contrast to females, in males passive immunization against GHRH resulted in a simultaneous increase in the markers of bone resorption and bone formation, a finding that could account for the maintenance of bone balance. Despite the slower gain in body weight recorded at 2 months of age, GHRH-Ab-treated males did not show any change in bone mass.
Further studies on the relationship between GH deficiency and sex steroids and/or calcium regulating hormones are warranted to explain the gender differences on bone parameters following GHRH-Ab treatment.
